21 July 2020
AstraZeneca has reported positive data from the Phase I/II COV001 clinical trial of Covid-19 vaccine, AZD1222, which is being developed by the University of Oxford. Early data showed that the vaccine candidate was tolerated and generated strong immune responses in all evaluated participants. Findings have been published in The Lancet journal.
UK-based Synairgen has reported positive clinical data of its inhaled interferon beta candidate, SNG001, for the treatment of patients hospitalised with Covid-19. The therapeutic was found to reduce the risk of developing severe disease by 79%, when compared to placebo. Synairgen added that patients on SNG001 were more than twice as likely to recover.
Pfizer and BioNTech have announced that their Covid-19 vaccine candidate, BNT162b1, produced dose-dependent SARS-CoV-2-neutralising titers following the second dose in a Phase I/II clinical trial being performed in Germany. The company added that the product for the first time demonstrated a concurrent induction of CD4+ and CD8+ T cell responses against the virus' receptor binding domain (RBD).
Japanese pharmaceutical firm Shionogi has plans to increase manufacturing capacity to produce enough doses of its Covid-19 vaccine for 30 million people each year by the end of 2021, according to Reuters. The aim is to triple the domestic production capacity.
In a mid-stage clinical trial, CanSino Biologics’ Covid-19 vaccine candidate Ad5-nCOV has shown positive safety profile and stimulated immune responses in the majority of participants. The vaccine was tested in a total of 508 subjects and demonstrated ability to induce both antibody and T-cell immune responses, without any serious side effects.